- Up to $100,000 to be awarded for an innovative solution addressing an unmet need in the graft-versus-host disease (GVHD) community
- Visit www.IncyteIngenuityAward.com to apply now!
Incyte (Nasdaq:INCY) is proud to announce the opening call for submissions for its newly launched Incyte Ingenuity Award, an annual program created to support people living with graft-versus-host disease (GVHD), as well as their caregivers and physicians, by encouraging innovative and novel solutions for the challenges currently facing the GVHD community. Each year, the Incyte Ingenuity Award is expected to fund, up to $100,000, one innovative program, idea or initiative that fosters collaboration within the GVHD community to address a specific unmet need.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200219005221/en/
"At Incyte, we wanted to create a community-driven program dedicated to improving the lives of patients with a serious disease, such as GVHD, which can be difficult to treat and have a devastating impact on the lives of patients," said Barry Flannelly, Pharm. D., Executive Vice President and General Manager, U.S., Incyte. "Through the Incyte Ingenuity Award, we hope to spark creativity and innovation, which we expect to result in impactful and actionable solutions for the GVHD community."
Submissions are welcomed from non-profit 501(c)(3), patient, policy and caregiver organizations, as well as healthcare providers and mid-level/junior faculty from healthcare organizations. Applications are due by April 30, 2020. All applications will be reviewed and evaluated by an independent judging panel, consisting of Gerry Cowden, Founder, Meredith Cowden Foundation; Shrina Duggal, PharmD, BCOP, Clinical Pharmacy Specialist; and Navneet Majhail, M.D., Director, Blood and Marrow Transplant Program, Cleveland Clinic. The judging panel will review each application and select the top three entries, who will then submit a more detailed proposal of their initiative. The first award recipient of Incyte Ingenuity Award will be announced in August of 2020.
"Through my practice, I see first-hand the struggles faced by those impacted by GVHD. Everywhere they turn, patients experience a limitation – whether it is through limited support, information and/or treatment options. This award and its outputs are expected to give the GVHD community hope for their future beyond this horrible disease," said Dr. Majhail. "I look forward to reviewing the submitted applications and seeing the brilliant initiatives that may come to fruition because of this generous award."
To apply and learn more about the eligibility criteria, visit www.IncyteIngenuityAward.com and submit an online application including a summary of the proposed initiative.
GVHD is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) where the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD, acute and chronic, that can affect multiple organ systems including the skin, gastrointestinal (digestive) tract, lung and liver.1
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
- Leukemia & Lymphoma Society. "Graft-Versus-Host Disease Facts." Available at: http://www.lls.org/treatment/types-of-treatment/stem-cell-transplantation/graft-versus-host-disease. Accessed January 2019.